Amneal Pharmaceuticals vs Elanco
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Amneal Pharmaceuticals and Elanco side by side, using each oneβs latest annual report. Here is what stands out:
- Elanco is the larger business, with $4.7B of revenue in fiscal 2025 against $3.0B for Amneal Pharmaceuticals, about 1.6 times as much.
- Amneal Pharmaceuticals grew revenue faster (8.1%, against 6.2%).
- Amneal Pharmaceuticals turned more of its sales into free cash flow (8.9% FCF margin, against 6.0%).
- Amneal Pharmaceuticals earned a higher return on the capital invested in it (16.1%, against β0.1%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Amneal Pharmaceuticals
AMRX
7/9
Revenue growth5-year growthNet marginFCF marginReturn on capitalPiotroski F-scoreNet debt / EBITDA
Elanco
ELAN
2/9
Gross marginShare count change
Side by side
Best in the row
| Latest fiscal year | AMRX FY25 | ELAN FY25 |
|---|---|---|
| Size | ||
| Market cap | $6.9B | $11.6B |
| Revenue | $3.0B | $4.7B |
| Free cash flow | $270M | $284M |
| Net income | $72.1M | β$232M |
| Growth | ||
| Revenue growth | 8.1% | 6.2% |
| 5-year growth | 8.7% | 7.6% |
| Share count change | 5.1% | β0.2% |
| Profitability | ||
| Gross margin | 36.9% | 55.0% |
| Operating margin | 13.1% | β |
| Net margin | 2.4% | β4.9% |
| FCF margin | 8.9% | 6.0% |
| Return on capital | 16.1% | β0.1% |
| Return on equity | β | β3.7% |
| Balance sheet | ||
| Net debt | $2.3B | $3.5B |
| Net debt / EBITDA | 3.8x | 5.2x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 42.9x | β |
| Piotroski F-score | 7 | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.